{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"91.9","value":"145.0"},{"groupId":"OG002","spread":"59.0","value":"84.0"},{"groupId":"OG003","spread":"46.9","value":"110.0"},{"groupId":"OG004","spread":"77.0","value":"134.3"},{"groupId":"OG005","spread":"72.4","value":"152.5"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.3","value":"-80.0"},{"groupId":"OG002","spread":"27.0","value":"-16.0"},{"groupId":"OG003","spread":"76.2","value":"10.0"},{"groupId":"OG004","spread":"40.0","value":"-30.0"},{"groupId":"OG005","spread":"108.1","value":"-40.8"}]}],"title":"Change from Baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"description":"IGF-1R expression was measured in pre- and post-dose tumor biopsy samples using an IHC assay as a function of time and dose. Results were expressed as an IGF-1R membrane H-score which could range from 0 to 300; with a score of 0 representing the absence of IGF-1R expression and an H-score of 300 representing maximum IGF-1R expression. Changes in IGF-1R expression levels from Baseline are summarized for all participants for whom these paired data were available. A post-dose decrease in IGF-1R membrane H-score was an indication of target engagement by dalotuzumab. A larger decrease in H-score correlated with a greater target engagement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received dalotuzumab 1.25 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG000","title":"Dalotuzumab 1.25 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 2.5 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG001","title":"Dalotuzumab 2.5 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 5 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG002","title":"Dalotuzumab 5 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 10 mg/kg IV infusion Q1W.","id":"OG003","title":"Dalotuzumab 10 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 15 mg/kg IV infusion Q1W.","id":"OG004","title":"Dalotuzumab 15 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 20 mg/kg IV infusion Q1W or Q2W.","id":"OG005","title":"Dalotuzumab 20 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 30 mg/kg (20 mg/mL) IV infusion Q3W.","id":"OG006","title":"Dalotuzumab 30 mg/kg Q3W (20 mg/mL)"}],"paramType":"MEAN","populationDescription":"The population consisted of all evaluable participants who received \\>90% of intended drug volume and had IGF-1R tumor pharmacodynamics measurements at Baseline and at least once during treatment. No data were available for the Dalotuzumab 2.5 mg/kg Q1W and Dalotuzumab 30 mg/kg Q3W treatment groups.","reportingStatus":"POSTED","timeFrame":"Predose in Cycle 1 (Baseline) and predose in Cycle 3 (Week 4)","title":"Change From Baseline in IGF-1R Protein Expression Level H-score in Tumor Samples","type":"SECONDARY","unitOfMeasure":"H-score"}